The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers

被引:22
作者
Wang, Qiao-Xuan [1 ,2 ]
Qu, Chun-Hua [1 ,3 ]
Gao, Yuan-Hong [1 ,2 ]
Ding, Pei-Rong [1 ,4 ]
Yun, Jing-Ping [1 ,3 ]
Xie, Dan [1 ,3 ]
Cai, Mu-Yan [1 ,3 ]
机构
[1] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China
[2] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, Guangzhou 510060, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Pathol, Guangzhou 510060, Peoples R China
[4] Sun Yat Sen Univ, Dept Colorectal Surg, Canc Ctr, Guangzhou 510060, Peoples R China
关键词
dMMR/MSI-H; Anti-PD-1; immunotherapy; Colorectal cancer; NIVOLUMAB; TUMORS;
D O I
10.1186/s40164-020-00193-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicting the subset in this group that will benefit from PD-1 blockade remains a challenge. In this study, we aimed to investigate the relationship between the degree of microsatellite instability and the responses to anti-PD-1 immunotherapy. 33 patients with colorectal adenocarcinoma who had a known MSI status and received anti-PD-1 immunotherapy were included. PCR results for MSI of the whole cohort were collected and treatment response was evaluated. Our data indicated that objective response rate (ORR) in instability-high group (instability loci >= 3) was significantly higher than ORR in instability-intermediate group (13/16 versus 6/17, P=0.008). Besides, patients in instability-high group had significant longer progression-free survival (log-rank test, P=0.004), and a significant increase in T lymphocyte infiltration and cytolytic activity in tumors. Future study might implement the intensity of microsatellite instability for more delicate selection for anti-PD-1 therapy in patient with dMMR/MSI-H tumors.
引用
收藏
页数:4
相关论文
共 6 条
[1]   The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes [J].
Kim, Tae-Min ;
Laird, Peter W. ;
Park, Peter J. .
CELL, 2013, 155 (04) :858-868
[2]   PD-1 Blockade in Tumors with Mismatch-Repair Deficiency [J].
Le, D. T. ;
Uram, J. N. ;
Wang, H. ;
Bartlett, B. R. ;
Kemberling, H. ;
Eyring, A. D. ;
Skora, A. D. ;
Luber, B. S. ;
Azad, N. S. ;
Laheru, D. ;
Biedrzycki, B. ;
Donehower, R. C. ;
Zaheer, A. ;
Fisher, G. A. ;
Crocenzi, T. S. ;
Lee, J. J. ;
Duffy, S. M. ;
Goldberg, R. M. ;
de la Chapelle, A. ;
Koshiji, M. ;
Bhaijee, F. ;
Huebner, T. ;
Hruban, R. H. ;
Wood, L. D. ;
Cuka, N. ;
Pardoll, D. M. ;
Papadopoulos, N. ;
Kinzler, K. W. ;
Zhou, S. ;
Cornish, T. C. ;
Taube, J. M. ;
Anders, R. A. ;
Eshleman, J. R. ;
Vogelstein, B. ;
Diaz, L. A., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2509-2520
[3]   Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 [J].
Le, Dung T. ;
Kim, Tae Won ;
Van Cutsem, Eric ;
Geva, Ravit ;
Jager, Dirk ;
Hara, Hiroki ;
Burge, Matthew ;
O'Neil, Bert ;
Kavan, Petr ;
Yoshino, Takayuki ;
Guimbaud, Rosine ;
Taniguchi, Hiroya ;
Elez, Elena ;
Al-Batran, Salah-Eddin ;
Boland, Patrick M. ;
Crocenzi, Todd ;
Atreya, Chloe E. ;
Cui, Yi ;
Dai, Tong ;
Marinello, Patricia ;
Diaz, Luis A., Jr. ;
Andre, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) :11-+
[4]   CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response [J].
Mandal, Rajarsi ;
Samstein, Robert M. ;
Lee, Ken-Wing ;
Havel, Jonathan J. ;
Wang, Hao ;
Krishna, Chirag ;
Sabio, Erich Y. ;
Makarov, Vladimir ;
Kuo, Fengshen ;
Blecua, Pedro ;
Ramaswamy, Apoorva T. ;
Durham, Jennifer N. ;
Bartlett, Bjarne ;
Ma, Xiaoxiao ;
Srivastava, Raghvendra ;
Middha, Sumit ;
Zehir, Ahmet ;
Hechtman, Jaclyn F. ;
Morris, Luc G. T. ;
Weinhold, Nils ;
Riaz, Nadeem ;
Le, Dung T. ;
Diaz, Luis A., Jr. ;
Chan, Timothy A. .
SCIENCE, 2019, 364 (6439) :485-+
[5]   Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer [J].
Overman, Michael J. ;
Lonardi, Sara ;
Wong, Ka Yeung Mark ;
Lenz, Heinz-Josef ;
Gelsomino, Fabio ;
Aglietta, Massimo ;
Morse, Michael A. ;
Van Cutsem, Eric ;
McDermott, Ray ;
Hill, Andrew ;
Sawyer, Michael B. ;
Hendlisz, Alain ;
Neyns, Bart ;
Svrcek, Magali ;
Moss, Rebecca A. ;
Ledeine, Jean-Marie ;
Cao, Z. Alexander ;
Kamble, Shital ;
Kopetz, Scott ;
Andre, Thierry .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) :773-+
[6]   Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study [J].
Overman, Michael J. ;
McDermott, Ray ;
Leach, Joseph L. ;
Lonardi, Sara ;
Lenz, Heinz-Josef ;
Morse, Michael A. ;
Desai, Jayesh ;
Hill, Andrew ;
Axelson, Michael ;
Moss, Rebecca A. ;
Goldberg, Monica V. ;
Cao, Z. Alexander ;
Ledeine, Jean-Marie ;
Maglinte, Gregory A. ;
Kopetz, Scott ;
Andre, Thierry .
LANCET ONCOLOGY, 2017, 18 (09) :1182-1191